<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic treatment for Legionnaires' disease in adults (&lt;em&gt;Legionella&lt;/em&gt; pneumonia)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic treatment for Legionnaires' disease in adults (<em>Legionella</em> pneumonia)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic treatment for Legionnaires' disease in adults (<em>Legionella</em> pneumonia)</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Preferred options</td> <td class="subtitle1">Alternative options*</td> </tr> <tr class="divider_bottom"> <td><strong>Mild pneumonia</strong><sup>¶</sup></td> <td> <ul> <li>Azithromycin 500 mg orally once daily<sup>Δ</sup></li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Levofloxacin 750 mg orally once daily<sup>Δ</sup><sup>◊</sup></li> </ul> </td> <td> <ul> <li>Ciprofloxacin 500 mg orally twice daily<sup>◊</sup></li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Moxifloxacin 400 mg orally once daily</li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Clarithromycin 500 mg orally twice daily<sup>◊</sup></li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Erythromycin (base) 500 mg orally four times daily</li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Roxithromycin 300 mg orally daily or 150 mg orally twice daily<sup>§</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Moderate or severe pneumonia</strong><sup>¶</sup><sup>¥</sup></td> <td> <ul> <li>Azithromycin 500 mg IV or orally once daily</li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Levofloxacin 750 mg IV or orally once daily<sup>◊</sup></li> </ul> </td> <td> <ul> <li>Ciprofloxacin 400 mg IV twice daily<sup>◊</sup> or 750 mg orally twice daily</li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Moxifloxacin 400 mg IV or orally once daily</li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Clarithromycin 500 mg IV or orally twice daily<sup>◊</sup><sup>‡</sup></li> <li style="list-style-type: none;"><strong>OR</strong></li> <li>Erythromycin (base) 1000 mg IV four times daily or 500 mg orally four times daily</li> </ul> </td> </tr> <tr> <td colspan="3"><strong>Duration of therapy:</strong></td> </tr> <tr> <td class="indent1" colspan="3">The minimum duration of therapy is 5 days for patients who have been afebrile and clinically stable for 48 hours. Patients with mild infection generally require 5 to 7 days of therapy. Patients with severe infection or chronic comorbidities generally require 7 to 10 days of therapy. Extended courses may be needed for immunocompromised patients or those with complications (eg, empyema or extrapulmonary infection).</td> </tr> </tbody></table></div><div class="graphic_footnotes">IV: intravenously; CRB-65: confusion, respiratory rate, blood pressure, 65 years of age and older; CURB-65: confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age and older; PSI: pneumonia severity indices.<br/>
* Tetracyclines (eg, doxycycline) are active against many Legionella species; however, because resistance is common for <em>L. longbeachae</em>, we generally do not use tetracyclines for treatment.<br/>
¶ Mild pneumonia refers to patients with CRB-65 or CURB-65 scores of 0 or PSI of I to II. Moderate to severe pneumonia is defined as any hospitalized patient or patient with a CRB-65 or CURB-65 scores ≥1 or PSI &gt;II. Severity scores must be placed in the context of other clinical information.<br/>
Δ For patients with mild pneumonia, it is not necessary to change to a preferred agent if they are responding to an active alternative agent.<br/>
◊ Dose adjustment is required for renal dysfunction.<br/>
§ Roxithromycin is not available in the United States.<br/>
¥ Initial therapy with an intravenous preparation is preferred for most hospitalized patients. Intravenous therapy can be switched to oral therapy once patients are clinically improving, hemodynamically stable, and able to tolerate oral antibiotics.<br/>
‡ The intravenous formulation of clarithromycin is not available in the United States.</div><div id="graphicVersion">Graphic 117791 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
